Viewing Study NCT00002753



Ignite Creation Date: 2024-05-05 @ 9:27 AM
Last Modification Date: 2024-10-26 @ 9:03 AM
Study NCT ID: NCT00002753
Status: COMPLETED
Last Update Posted: 2013-02-18
First Post: 1999-11-01

Brief Title: Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
Sponsor: Duke University
Organization: Duke University

Study Overview

Official Title: PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS
Status: COMPLETED
Status Verified Date: 2013-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: RATIONALE Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells

PURPOSE Phase I trial to determine the effectiveness of monoclonal antibody in treating patients with recurrent gliomas
Detailed Description: OBJECTIVES I Assess the toxic effects of intracystic administration of iodine-131-labeled anti-tenascin monoclonal antibody 81C6 II Identify any objective therapeutic responses to this treatment in patients with recurrent cystic anaplastic gliomas

OUTLINE Radioimmunotherapy Iodine-131-Labeled Anti-Tenascin Monoclonal Antibody 81C6 131I-81C6

PROJECTED ACCRUAL Three to six patients will be entered at each dose studied

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
NCI-H96-0008 None None None
DUMC-1775-95-12R4 None None None
DUMC-1752-96-12R5 None None None
DUMC-1965-98-12R7 None None None
DUMC-1860-97-12R6 None None None